Investors
-
March 18, 2025Umecrine Cognition provides update on the Phase 1b/2a clinical study of golexanoloneSTOCKHOLM – March 18, 2025. Umecrine Cognition today announces that its Phase 1b/2a study of golexanolone has been delayed due to technical issues...
-
March 17, 2025Umecrine Cognition will attend BIO-Europe Spring® 2025 in MilanSTOCKHOLM – March 19, 2025. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Milan, Italy. The meeting takes...
-
January 13, 2025Umecrine Cognition attends the 43rd Annual JP Morgan Healthcare ConferenceSTOCKHOLM – January 13, 2024. Umecrine Cognition today announced that the company will attend the 43rd Annual J.P. Morgan Healthcare Conference in...
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.